Navigation Links
ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
Date:12/6/2011

h the Securities and Exchange Commission for the periods ended March 31, 2011, June 30, 2001 and September 30, 2011, could cause future results to differ materially from the expectations expressed in this press release. The forward-looking statements contained in this press release are made as of the date hereof and may become outdated over time. ViroPharma does not assume any responsibility for updating any forward-looking statements. These forward looking statements should not be relied upon as representing our assessments as of any date subsequent to the date of this press release.

Halozyme Safe Harbor Statement

 In addition to historical information, the statements set forth above regarding the subcutaneous Cinryze with rHuPH20 product candidate, its possible advantages and attributes,  the anticipated presentation of the complete data from the initial Phase 2 trial referenced in this press release, future clinical trials plans, including the anticipated Phase 2 dose ranging efficacy combination trial, and other statements regarding Halozyme's product candidates and potential attributes of these product candidates, involve risk and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are also identified through use of the words "expect," "believe," "enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict," "probable," "potential," "possible," "should," "continue," and other words of similar meaning.  Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including clinical trial results, delays in development, possible adverse events associated with the use of the product candidate, regulatory delays and competitive conditions. These and other factors that may result in differences are discussed in greater de
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. ViroPharma to Participate in Two November Healthcare Investor Conferences
2. ViroPharma to Acquire DuoCort Pharma AB, Adding Important European Orphan Drug to Commercial Pipeline
3. ViroPharma Incorporated Reports Third Quarter 2011 Financial Results
4. ViroPharma to Release 2011 Third Quarter Financial Results on October 27, 2011
5. ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia
6. ViroPharma Announces Additional Securities Repurchase Program
7. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
8. ViroPharmas Buccolam® (Midazolam, Oromucosal Solution) Granted European Marketing Authorization for Treatment of Acute Seizures
9. ViroPharma to Participate in the Stifel Nicolaus 2011 Healthcare Conference
10. ViroPharma Announces Positive CHMP Opinion for Buccolam® (Midazolam, Oromucosal Solution) in the European Union
11. ViroPharmas Cinryze® (C1 Inhibitor [Human]) Granted European Marketing Authorization for Hereditary Angioedema (HAE)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 Across the global ... meeting challenges in clinical development, market education, and regulatory ... the Medical Affairs function is expected to increase in ... According to research by benchmarking firm, ... a group dedicated to Medical Affairs. Among companies in ...
(Date:3/27/2015)... , March 27, 2015 /PRNewswire/ - Medicure Inc. (the ... Directors has approved the grant of an aggregate of ... employees and consultants of the Company pursuant to the ... set to expire on the tenth anniversary of the ... the third anniversary of the date of grant and ...
(Date:3/27/2015)... VICTORIA, Texas , March 27, 2015  Victoria Vein ... removal services with the Astanza Duality laser in ... of vein disease as well as advanced laser treatments for ... are entering the tattoo industry to provide more services for ... Surgery has helped many Victoria residents ...
Breaking Medicine Technology:Medical Affairs Capabilities Expanding in Emerging Marketplaces 2Victoria Vein And Surgery Clinic Uses Advanced Astanza Duality Tattoo Removal Technology 2
... Sept. 27, 2011 Masimo ... that findings from a new study published in the ... noninvasive and continuous hemoglobin (SpHb®) monitoring has absolute and ... hemoglobin measurement with additional advantages.  Study highlights that "the ...
... the United States Food and Drug Administration ("FDA") said its ... fold increase risk of blood clots for women who use ... The safety of Yaz and Yasmin is the subject ... of Common Pleas Judge Sandra Mazer Moss, Coordinating Judge of ...
Cached Medicine Technology:Published Study Demonstrates the Absolute and Trend Accuracy of Masimo Noninvasive and Continuous Total Hemoglobin (SpHb) Monitoring in Intensive Care Unit Patients 2Published Study Demonstrates the Absolute and Trend Accuracy of Masimo Noninvasive and Continuous Total Hemoglobin (SpHb) Monitoring in Intensive Care Unit Patients 3Published Study Demonstrates the Absolute and Trend Accuracy of Masimo Noninvasive and Continuous Total Hemoglobin (SpHb) Monitoring in Intensive Care Unit Patients 4Published Study Demonstrates the Absolute and Trend Accuracy of Masimo Noninvasive and Continuous Total Hemoglobin (SpHb) Monitoring in Intensive Care Unit Patients 5Published Study Demonstrates the Absolute and Trend Accuracy of Masimo Noninvasive and Continuous Total Hemoglobin (SpHb) Monitoring in Intensive Care Unit Patients 6FDA Issues Safety Communication Regarding Increased Risk of Blood Clots with Certain Birth Control Pills 2
(Date:3/28/2015)... 28, 2015 Pitching speed, player’s height, and ... shoulder and elbow injuries, according to new research released today ... ) Specialty Day. , “Our findings indicate that a 10 ... in likelihood of a history of injury, a 10 mile ... increase likelihood of a history of injury, and playing for ...
(Date:3/28/2015)... Delaying rotator cuff surgery on patients ... research presented today at the American Orthopaedic Society for ... study compared results for 170 patients who received rotator ... joint capsule release procedure to relieve stiffness at the ... author from St. George Hospital in Sydney, Australia. “Both ...
(Date:3/28/2015)... San Francisco, California (PRWEB) March 28, 2015 ... search for original 1960's Who psychedelic concert posters. The Who ... Flushing, New York on August 2, 1968. According to Hawley, ... 1969 playing many concert halls and college campuses. Perhaps the ... their performance with Jim Morrison and the Doors on August ...
(Date:3/28/2015)... March 28, 2015 Healthpointe’s otolaryngologists, medical ... and throat disorders, are now offering a wide ... issue which is characterized by the presence of phantom ... 5 people, tinnitus is a prevalent symptom that can ... it is non-fatal, tinnitus can impede a person’s quality ...
(Date:3/28/2015)... ARDX will sponsor the 7th Annual Women’s Wellness Celebration ... Conference Center in Chesapeake, Virginia. Each year, ARDX celebrates ... in the Hampton Roads region. The 2015 Women’s History ... Women grow stronger through sharing their stories and learning the ... WWC™ theme is T-talk where we will share a cup ...
Breaking Medicine News(10 mins):Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2
... - CRH Medical Corporation,(CRM:TSX-V) announced today that it has ... Island. This Center is the Company,s first in the,state ... CRH has targeted for,expansion. The opening of this location ... Company,s total number of Centers to 14., According ...
... (IDF) BRIDGES translational research grant program will fund a ... for people at high-risk for getting type 2 diabetes ... develop a healthy lifestyle. , The National Hospital of ... Vietnam. Using diabetes risks questionnaires (1) , the investigators ...
... May 15 Gerson Lehrman Group, the world,s,leading ... a Web-based community devoted to providing patients with ... own healthcare.,iGuard.org provides personalized iGuard Risk Ratings, iGuard ... their experience with other registered,users who also want ...
... Pain is a chief reason that,patients seek ... these patients. Physicians must be able to determine ... their patients., To make clinicians aware of ... dual journals Current Clinical Practice and The,Journal of ...
... cancer patients and menopausal women, study finds , , THURSDAY, ... local anesthetic into the nerves of the neck that ... from hot flashes and sleep deprivation, a new study ... breast cancer, especially among women taking anti-estrogen drugs. These ...
... invites shareholders and investors to listen to a broadcast ... and a discussion,of the outlook for the fourth quarter., ... over the Internet on,Thursday, May 15, 2008 at 4:30 ... Company,s website at http://www.pro-dex.com . Mark Murphy,Chief Executive ...
Cached Medicine News:Health News:CRH Medical Corporation opens Center in New York 2Health News:International Diabetes Federation gives grant to diabetes screening & prevention program in Vietnam 2Health News:Gerson Lehrman Group and iGuard, Inc. Partner to Offer Patients a Voice in Healthcare Industry Decisions 2Health News:Gerson Lehrman Group and iGuard, Inc. Partner to Offer Patients a Voice in Healthcare Industry Decisions 3Health News:Treat Your Patients' Pain Effectively 2Health News:Hot Flashes Reduced by Neck Injection 2Health News:Hot Flashes Reduced by Neck Injection 3Health News:Pro-Dex, Inc. Announces Fiscal 2008 Third Quarter Financial Results Conference Call and Webcast 2
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: